5 Insights on

• Increased Interferon-Alpha Production
• Enhanced Natural Killer Cell Activity
• Increased Interleukin-12 Production
• Improved Survival Rate Against Influenza Virus
• Reduced Influenza Virus Titer

14 Insights on

• Reduced Total Cholesterol Levels
• Reduced Body Weight
• Reduced Serum Cholesterol Levels
• Reduced LDL Cholesterol
• Reduced Cholesterol Levels
• Reduced Serum Total Cholesterol Levels
• Reduced Atherogenic Index
• Relieved Constipation
• Reduced Constipation
• Increased Fecal Water Content
• Reduced Body Weight Gain
• Increased Lower Body Weight
• Improved Fecal Water Content
• Reduced Arterial Stiffness

6 Insights on

• Reduced Liver Inflammation
• Reduced Plasma Lipopolysaccharide Levels
• Reduced Liver Injury
• Improved Gut Microbiome Composition
• Reduced Oxidative Stress
• Reduced Serum Transaminase Levels

5 Insights on

• Increased Vaginal Lactobacilli Levels
• Reduced Malodorous Discharge
• Increased Cure Rate
• Vaginal Colonization by Lactobacillus Strains
• Increased Cure Rate after Conventional Treatment

3 Insights on

• Increased Body Weight
• Improved Iron Levels
• Reduced Prevalence of Anemia

8 Insights on

• Improved Growth Performance
• Enhanced Disease Resistance
• Improved Immunity
• Reduced Vibrio Counts in Intestine
• Enhanced Phagocytic Activity
• Increased Total Coelomocyte Count
• Increased Viable Bacteria Count
• Reduced Vibrio Counts

31 Insights on

• Reduced Body Mass Index
• Reduced Faecal pH
• Reduced Intestinal Permeability
• Reduced Enterobacteriaceae Counts
• Reduced Clostridium Counts
• Reduced Faecal Calprotectin
• Increased Fecal Bifidobacteria Levels
• Increased Short Chain Fatty Acids
• Increased Fecal Bifidobacteria
• Increased Fecal Immunoglobulin A Concentrations
• No Change in Risk of Necrotizing Enterocolitis
• No Change in Sepsis Risk
• No Change in Antibiotic Usage
• No Adverse Events Observed
• Increased Fecal Immunoglobulin A Levels
• Absence of Adverse Events
• Reduced Enterobacterial Counts
• Reduced Fecal Calprotectin
• No Change in Risk of Stage 2 or Higher Necrotizing Enterocolitis
• Increased Antibiotic Use
• Reduced Clostridium Species Counts
• Increased Short-Chain Fatty Acids Concentrations
• Reduced Stool pH
• No Adverse Events Associated with B Lactis Supplementation
• Increased Risk of Necrotizing Enterocolitis Stage 2 or Higher
• Increased Risk of Sepsis
• Unchanged Use of Antibiotics
• Adverse Events Due to Supplementation
• No Reduced Risk of Necrotizing Enterocolitis
• Unchanged Risk of Sepsis
• No Reduction in Antibiotic Use

1 Insight on

• Reduced Risk of Gonorrhea Infection

3 Insights on

• Reduced Harmful Gut Bacteria
• Increased Polyunsaturated Fatty Acids in Milk
• Increased Beneficial Gut Lactic Acid Bacteria

7 Insights on

• Improved Gut Microbiota
• Improved Bowel Movement Frequency
• Increased Fecal Lactobacilli
• Improved Immune Response
• Increased Interleukin-10 Levels
• No Reported Adverse Effects
• Increased Plasma Immunoglobulin Levels

10 Insights on

• Reduced Vomiting Frequency
• Reduced Incidence of Upper Respiratory Tract Infections
• Reduced Respiratory Symptoms
• Reduced Diarrhea Episodes
• Reduced Duration of Upper Respiratory Tract Infection
• Reduced Respiratory Symptom Days
• Reduced Risk of Prolonged Respiratory Infections
• No Significant Reduction in Lower Respiratory Tract Infections
• No Reduction in Gastrointestinal Infections
• No Significant Change in Duration of Gastrointestinal Symptoms

9 Insights on

• Improved Intestinal Barrier Function
• Increased Tight Junction Protein Levels
• Improved Epithelial Permeability
• Improved Epithelial Barrier Function
• Improved Tight Junction Protein Localization
• Reduced Epithelial Permeability
• Improved Epithelial Integrity
• Improved Intestinal Epithelial Barrier Function
• Reduced Epithelial Barrier Disruption

2 Insights on

• Improved Gut Microbiota
• Improved General Health

2 Insights on

• Alleviated Intestinal Disease
• Enhanced Host Well-being

2 Insights on

• Improved Bowel Movement Frequency
• Improved Liver Function

2 Insights on

• Improved Atopic Eczema-Dermatitis Symptoms
• Reduced Serum Chemokine Levels

1 Insight on

• No Adverse Translocation

12 Insights on

• Increased Body Weight
• Improved Growth Performance
• Improved Cell Survival Rates
• Improved Shear Force of Meat
• Reduced Drip Loss in Meat
• Reduced Drip Loss
• Increased Survival Rate
• No Significant Change in Breast Composition
• Maintained pH Levels
• Increased Shear Force
• Reduced Shear Force
• Altered Breast Chemical Composition

1 Insight on

• Increased Th17 Polarization

3 Insights on

• Reduced Incidence of Adverse Events
• Increased Adverse Events
• Increased Safety in Vulnerable Populations

3 Insights on

• Reduced Serum Triacylglycerols
• Reduced LDL Cholesterol
• Increased Fecal Bile Acid Levels

15 Insights on

• Reduced Incidence of Loose Stools
• Reduced Nausea
• No Change in Severe Diarrhea Incidence
• Reduced Risk of Diarrhea
• No Significant Effect on Diarrhea
• No Significant Effect on Toxin-Producing C. difficile Carriage
• No Impact on Severe Diarrhea
• No Impact on Clostridium difficile Toxin Carriage
• No Change in Diarrhea
• Unchanged Severe Diarrhea
• Unchanged Incidence of Diarrhea
• Reduced Incidence of Loose or Watery Stools
• Reduced Nausea Incidence
• Increased Diarrhea Incidence
• Carriage of Toxin-Producing Clostridium Difficile

2 Insights on

• Improved Safety Profile
• Unchanged Symptom Severity

3 Insights on

• Improved Microbial Diversity
• Reduced Isovaleric Acid Concentration
• Reduced Valeric Acid Levels

3 Insights on

• Reduced Inflammatory Markers
• Reduced Colitis Symptoms
• Reduced NF-kappaB Nuclear Translocation

3 Insights on

• Improved Glucose Tolerance
• Reduced Blood Glucose Levels
• Prevention of Weight Loss

3 Insights on

• Reduced Pro-Inflammatory Cytokines
• Improved Intestinal Barrier Integrity
• Incidence of Necrotizing Enterocolitis

7 Insights on

• Improved Gut Health
• Ensured Safety for Human Consumption
• Enhanced Immune Function
• Absence of Acute Toxicity
• No Subchronic Toxicity
• No Mutagenic Effects
• Absence of Subacute Toxicity

3 Insights on

• Reduced Tumor Growth
• Inhibited EGF Receptor Signaling
• Inactivated Other Receptor Tyrosine Kinase Activity

6 Insights on

• Prolonged Survival Time in Influenza Infection
• Reduced Lung Viral Titers
• Enhanced Protection Against Influenza Infection
• Increased Interferon Production
• Reduced Lung Viral Titers After Influenza
• Increased Serum Interferon-Beta Level